Self-powered wearable diagnosis and treatment integrated patch for specific dermatitis, preparation method and application

By designing a self-energized wearable diagnosis and treatment integrated patch, using rechargeable power and temperature-controlled treatment microneedle, the intelligent delivery problem of atopic dermatitis detection and treatment is solved, and rapid and accurate skin condition monitoring and personalization are achieved. Treatment reduced side effects and significantly shortened the spleen length of mice with specific dermatitis.

CN119075163AActive Publication Date: 2024-12-06UNIV OF ELECTRONICS SCI & TECH OF CHINA
View PDF 14 Cites 0 Cited by

Patent Information

Application Number
CN202411200463.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-29
Publication Date
2024-12-06
Estimated Expiration
2044-08-29

AI Technical Summary

Technical Problem

The existing atopic dermatitis detection and treatment methods are difficult to achieve intelligent drug delivery, and most of the existing equipment are single-function and cannot be combined with the treatment module to achieve integrated detection and treatment, and there are problems of side effects and adverse reactions.

Method used

A self-energized wearable diagnostic and treatment integrated patch is designed, using rechargeable power, flexible circuit module and temperature-controlled treatment microneedle to measure the moisture content through the thermal effect of the skin, and automatically determine whether microneedle needs to be released for drug delivery, so as to achieve no Battery, portable skin moisture measurement and specific dermatitis treatment.

Benefits of technology

Fast and accurate skin condition monitoring and personalized treatment were achieved, reducing side effects and significantly shortening the spleen length of mice with specific dermatitis, demonstrating the effectiveness and safety of the device.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119075163A_ABST
    Figure CN119075163A_ABST
Patent Text Reader

Abstract

The invention provides a self-powered wearable diagnosis and treatment integrated patch for specific dermatitis, a preparation method and application thereof, the patch uses a rechargeable power supply as an energy source, and the rechargeable power supply can work by using energy converted from human body mechanical energy to electric energy based on a piezoelectric effect to realize energy supply of the rechargeable power supply. The patch provided by the invention measures the water content of the skin through the skin heat effect, and can quickly and accurately monitor the skin state. Health judgment is directly carried out through the measured skin water content, drug release is achieved without external intervention, and the whole treatment process is completed. The hyaluronic acid micro-needle array is integrated, so that the skin can be moisturized while antibiotic drugs are delivered in a percutaneous manner. The patch can be used for effectively and safely detecting and treating the specific dermatitis, and under the treatment of the patch, the spleen length of a mouse with the specific dermatitis is obviously shorter than that of an untreated mouse with the specific dermatitis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of wearable medical equipment in biomedical engineering, and in particular relates to a self-powered wearable integrated diagnosis and treatment patch for atopic dermatitis. Background Art

[0002] Atopic dermatitis (AD) is a chronic inflammatory skin disease that significantly affects the consumption of medical resources and the quality of life of patients. Up to 20% of children and 3% of adults worldwide are affected by AD. AD usually develops in early childhood, and about 50% of AD patients develop other allergic symptoms within the first year after birth. Up to 85% of patients may develop the disease before the age of 5, and may develop other allergic diseases as they age. The latest genetic studies have shown that defective skin barrier function is one of the key mechanisms for the onset of AD. Normal skin maintains a balance between lipid and water content. When this balance is broken, it will lead to dry skin and damaged barrier, which are typical symptoms of AD. Quantitative assessment of skin barrier function can provide important guidance for clinical decision-making. Common non-invasive methods for evaluating skin barrier include: observation of skin surface structure, determination of transepidermal water loss (TEWL) by measuring the water vapor pressure on the skin surface, and indirect assessment of water content by measuring the conductivity, capacitance or impedance of the skin. However, existing measuring instruments often use rigid electrode probes, which are difficult to fit well with the skin surface and have high requirements for the contact pressure and angle of the instrument. In addition, most of these instruments are bulky and expensive, making them inconvenient to carry around. Recently, researchers have developed a flexible skin hydration sensor based on thermal sensing, which has the advantages of being thin, conformable and easy to carry. It detects skin hydration by measuring the thermal properties of the skin surface. However, most of the existing sensors have a single function and are difficult to combine with treatment modules to achieve integrated detection and treatment. For patients with mild atopic dermatitis, current treatments mainly include skin moisturizing and the use of topical anti-inflammatory drugs; for more severe patients, topical steroid hormones or calcineurin inhibitors are used for treatment.

[0003] While these treatments achieve good results, they may also produce serious adverse reactions. For example, long-term use of hormones may lead to drug resistance, and long-term injections may cause local pain or even tissue necrosis. Therefore, more precise and effective treatments are urgently needed. Microneedles (MNs) have good application prospects as an alternative means of painless drug delivery and fewer side effects. Hyaluronic acid (HA), as an ideal polymer microneedle matrix, has attracted much attention due to its strong biocompatibility, water retention and human origin. Hyaluronic acid microneedles not only have sufficient mechanical strength to penetrate the stratum corneum, but can also be used for drug delivery. However, current measurement and treatment methods cannot achieve intelligent drug delivery based on the severity of the patient's dermatitis, and innovation and improvement are urgently needed on this basis. This self-powered wearable closed-loop microneedle system based on wireless technology and controlled by a smartphone will provide patients with atopic dermatitis with the flexibility of testing and treatment anytime and anywhere, and bring convenience to personalized skin disease management. By developing a microneedle system with drug delivery function, the device can not only achieve precise treatment, but also has the characteristics of strong biocompatibility. Transdermal drug delivery technology also shows great potential as a non-invasive and painless alternative. These innovations provide new hope for exploring and developing more effective treatments for atopic dermatitis. Summary of the invention

[0004] The purpose of the present invention is to design a wearable patch that integrates atopic dermatitis detection and treatment. The patch measures the skin's water content through the thermal effect of the skin to determine the patient's current physical condition, and confirms whether degradable microneedle drug delivery is needed based on the water content value, thereby achieving battery-free, portable skin water content measurement and atopic dermatitis treatment. The device is expected to fill the gap in this field in domestic and foreign research, and further expand the application of integrated diagnosis and treatment in the field of skin diseases.

[0005] To achieve the above-mentioned purpose, the present invention provides a self-powered wearable integrated diagnosis and treatment patch for atopic dermatitis. The patch uses a rechargeable power supply as an energy source. The rechargeable power supply is based on the piezoelectric effect and can utilize the energy converted from human mechanical energy into electrical energy to realize the energy supply of the rechargeable power supply.

[0006] In order to solve the above technical problems, a self-powered wearable integrated diagnosis and treatment patch for atopic dermatitis of the present invention comprises a rechargeable power source 1-1, a flexible circuit module 1-2 and a temperature-controlled therapeutic microneedle 1-3;

[0007] The rechargeable power source comprises two pieces of lead zirconate titanate piezoelectric ceramics stacked up and down and a stainless steel shell, wherein the two pieces of lead zirconate titanate piezoelectric ceramics are wrapped inside the stainless steel shell;

[0008] The flexible circuit module of the system includes a measurement module and a control chip, and the control chip controls the measurement module; the flexible circuit module is a double-layer circuit board, wherein the control chip is located on the upper circuit board and the measurement module is located on the lower circuit board;

[0009] Specifically, the measurement module includes a heating circuit 2-1, a measuring circuit 2-2 and a data extraction circuit 2-3; wherein the heating circuit serves as a heating release circuit for the microneedle, and the control chip generates a signal to power the heating circuit for heating; the measuring circuit is a differential circuit, which is connected to a rechargeable power supply as an energy source; the quantity extraction circuit uses the digital-to-analog conversion function of the control chip to enable the pin to read the voltage value of the differential circuit through the analog input and record it, and the heating circuit, the measuring circuit and the data extraction circuit remain electrically connected;

[0010] The temperature-controlled therapeutic microneedle includes a microneedle array matrix and a temperature-sensitive material. The surface of the microneedle array matrix is ​​coated with the temperature-sensitive material. When the measurement circuit detects that the drug needs to be released, the control chip releases a signal to make the heating release circuit of the microneedle heat the temperature-controlled therapeutic microneedle, and the temperature-sensitive material melts and becomes liquid, prompting the drug in the microneedle to be released.

[0011] The rechargeable power source, flexible circuit module and temperature-controlled therapeutic microneedles are connected to the flexible substrate through a reflow soldering process, and the control chip and the rechargeable power source are on the upper surface of the flexible substrate; the measurement module and the temperature-controlled therapeutic microneedles are located on the lower surface of the flexible circuit, and the components on the upper surface of the flexible substrate are encapsulated using polydimethylsiloxane.

[0012] The heating circuit is composed of two heating wires RH1 and RH2 connected in series, and the analog output of the control chip opening pin is pulse modulated to generate a pulse signal to power the heating wire;

[0013] The measuring circuit is composed of two resistors R1 and R2 and two negative temperature coefficient thermistors NTC+ and NTC-; NTC+ and R1 are one path, and NTC- and R2 are two paths connected in parallel to form a differential circuit; one end of the differential circuit is connected to a rechargeable power supply, and the other end is connected to a quantity extraction circuit, the quantity extraction circuit extracts the voltage values ​​of the two paths, and the control chip releases a signal to power the heating circuit.

[0014] The melting point of the thermosensitive material is 40-42 degrees Celsius; the thermosensitive material is tridecanoic acid, the microneedle array matrix is ​​hyaluronic acid, and is loaded with the antibiotic dexamethasone.

[0015] The present invention also provides a method for preparing a self-powered wearable integrated diagnosis and treatment patch for atopic dermatitis, comprising the following steps:

[0016] Step 1, designing a flexible circuit board; using electronic design automation software to design a circuit, and patterning a polyimide film to obtain a flexible substrate;

[0017] Step 2, welding of the flexible circuit board; integrating the rechargeable power source, the flexible circuit module and the temperature-controlled therapeutic microneedles on the flexible substrate; wherein the control chip in the flexible circuit module is integrated on the upper surface of the flexible substrate, the measurement module reflow soldering technology is integrated on the lower surface of the flexible substrate, and the various modules of the circuit are electrically connected;

[0018] Step 3: Use polydimethylsiloxane to encapsulate the upper surface of the flexible substrate in small amounts multiple times to ensure that the device remains insulated from the outside world after encapsulation, and cure at 80° C. for 2 hours.

[0019] The steps for preparing the temperature-controlled therapeutic microneedle are as follows:

[0020] Step 11, preparation of hyaluronic acid microneedles; prepare a hyaluronic acid aqueous solution, dissolve hyaluronic acid in water, and the concentration of hyaluronic acid in the solution is 150 mg / ml.

[0021] Step 12, adding dexamethasone sodium phosphate to the hyaluronic acid solution of step 1, and stirring the solution for more than 2 hours using a stirring bar and a magnetic stirrer, and finally obtaining a mixed solution containing dexamethasone sodium phosphate at an effective concentration;

[0022] Step 13, placing the solution obtained in step 12 into a microneedle mold, repeatedly evacuating the mold in a vacuum drying oven to remove bubbles, and then drying for 24 hours and then demolding to obtain a microneedle array matrix;

[0023] Step 14: Place the microneedle array matrix obtained in step 13 flat on a container, put the temperature-sensitive material into a spray bottle, heat it in a 70-degree Celsius oven to a liquid, and then spray it evenly on the surface of the microneedle array to form a uniform coating. After standing at room temperature for ten minutes, a microneedle array coated with the temperature-sensitive material is obtained.

[0024] Specifically, the effective concentration is 2.5 micrograms per milliliter.

[0025] The present invention also provides a method for constructing a mouse model of atopic dermatitis treated with an ultrasonic patch integrating treatment and monitoring, and using the patch as described above, the method comprises the following steps:

[0026] Step 21, modeling of mice with atopic dermatitis; using 1% dinitrochlorobenzene solution to stimulate atopic dermatitis in mice, and applying 1% dinitrochlorobenzene to the foot pads, abdomen, ears and back of mice every day for one week. The modeling is considered successful when atopic dermatitis-like appearance such as erythema, exudation, and epidermal exfoliation appears on the skin of the tested parts of the mice. After the modeling is successful, the mice are re-stimulated every two days during the treatment period;

[0027] Step 22, exposing the patch to ultraviolet light for 30 minutes in a laminar flow cell culture incubator to sterilize the patch;

[0028] Step 23, using the temperature-controlled therapeutic microneedles on the patch to insert the patch into the back epidermis of the mouse to complete the fixation of the device;

[0029] Step 24, open the patch circuit twice a day to detect the water content. If the drug is released after the test, replace the microneedle and repeat step 23 to fix the device on the back of the mouse. The whole experiment is carried out twice on the specific mice for 14 consecutive days, each test time is three minutes, and if there is drug release, the microneedle is replaced after one hour.

[0030] The beneficial effects of the present invention are as follows:

[0031] (1) Measuring skin moisture content through skin thermal effect can quickly and accurately monitor skin condition.

[0032] (2) The present invention directly determines the health of the skin by measuring the moisture content of the skin, and releases the drug without external intervention, thereby completing the entire treatment process.

[0033] (3) The present invention integrates a hyaluronic acid microneedle array, which can deliver antibiotic drugs transdermally and moisturize the skin at the same time.

[0034] (4) The device designed by the present invention can effectively and safely detect and treat atopic dermatitis. Under the treatment of the patch, the spleen length of atopic dermatitis mice was significantly shorter than that of untreated atopic dermatitis mice. BRIEF DESCRIPTION OF THE DRAWINGS

[0035] Figure 1 Schematic diagram of the integrated composition of skin water content measurement and drug release microneedle;

[0036] Figure 2 This is the circuit diagram of the skin moisture content measurement module;

[0037] Figure 3 The schematic diagram of the working process of the whole system is shown in Figure 2.

[0038] Figure 4 This is a graph showing the measurement results of skin moisture content;

[0039] Figure 5 SEM images of a microneedle array without tridecanoic acid coating (left) and a microneedle array coated with tridecanoic acid (right);

[0040] Figure 6 This is a statistical chart of spleen length in mice in animal experiments. DETAILED DESCRIPTION

[0041] In order to better understand the purpose, structure and function of the present invention, the following is a further detailed description of a self-powered wearable integrated diagnosis and treatment patch for atopic dermatitis, a preparation method and an application thereof in conjunction with the accompanying drawings.

[0042] Example 1

[0043] This embodiment provides a self-powered wearable integrated diagnosis and treatment patch for atopic dermatitis, such as Figure 1 As shown, it is a schematic diagram of the structure of a self-powered wearable integrated diagnosis and treatment patch for atopic dermatitis, the patch includes a rechargeable power source 1-1, a flexible circuit module 1-2 and a temperature-controlled treatment microneedle 1-3;

[0044] The rechargeable power source 1-1 is used as the energy source of the patch. The rechargeable power source can convert the mechanical energy generated by body movement into electrical energy through the piezoelectric ceramic sheet to charge it, and serve as the energy source of the system. The piezoelectric ceramic sheet is composed of two stacked lead zirconate titanate piezoelectric ceramics (Lead zirconate titanate piezoelectric ceramics, PZT) and a stainless steel shell; the lead zirconate titanate piezoelectric ceramics is rectangular, about 9 cm wide and about 5 cm long, and the stainless steel shell is a rectangle with a width of about 9.5 cm and a length of about 5.5 cm. Lead zirconate titanate piezoelectric ceramics are wrapped in a small amount of epoxy resin inside a stainless steel shell. Based on the piezoelectric effect, when the piezoelectric ceramic is subjected to a longitudinal external force, polarization will occur inside it, and its two upper and lower surfaces will show opposite positive and negative charges. When the external force disappears, it returns to an uncharged state. Therefore, when the piezoelectric ceramic is pressed by the outside world, it will convert the mechanical energy of the human body's pressure into a piezoelectric signal. When pressed, the output of the piezoelectric ceramic can reach about 20 volts and 20 microamperes, which can charge the rechargeable power supply.

[0045] The flexible circuit module 1-2 of the system includes a measurement module and a control chip, and the control chip electrically controls the circuit. The flexible circuit module is a double-layer circuit board, divided into two surfaces, the upper and lower surfaces, wherein the control chip is located on the upper circuit board and the measurement module is located on the lower circuit board.

[0046] like Figure 2As shown, it is a schematic diagram of the measurement module in the flexible circuit module 1-2, and the measurement module specifically includes a heating circuit 2-1, a measurement circuit 2-2 and a data extraction circuit 2-3; the heating circuit is composed of two heating wires RH1 and RH2 connected in series, and the analog output of the control chip opening pin is pulse modulated (PWM) to generate a pulse signal to power the heating wire, which serves as a heating release circuit for the microneedle; the measurement circuit is composed of two ordinary resistors R1 and R2 and two negative temperature coefficient thermistors NTC+ and NTC-. The measurement circuit is directly connected to the rechargeable power supply (VDD of 2-2) as an energy source, NTC+ and R1 are one way, and NTC- and R2 are one way. The two ways are connected in parallel to form a differential circuit. The GND of the heating circuit and the GND of the measurement circuit are finally converged and connected to the negative pole of the rechargeable power supply. The heat of the heating wire will cause the resistance value of the thermistor to change, which in turn affects the voltage at both ends of the data extraction circuit, and the difference in skin water content will lead to the difference in skin thermal effect, and then have different heat dissipation capabilities, so the voltage obtained by the skin data extraction circuit with different water content is different. The digital extraction circuit uses the digital-to-analog conversion function of the control chip to turn on the pin to read the voltage value through the analog input and record it. The heating circuit, the measuring circuit, and the data extraction circuit remain electrically connected.

[0047] The temperature-controlled therapeutic microneedles 1-3 include a microneedle array matrix and a temperature-sensitive material; the surface of the microneedle array matrix is ​​coated with a temperature-sensitive material, tridecanoic acid, which has a melting point of 41-42 degrees Celsius. Therefore, in a normal environment, tridecanoic acid is a solid material. When the measurement circuit detects that the drug needs to be released, the control chip releases a pulse signal to make the heating wire of the microneedle heating release circuit heat the microneedle, so that the tridecanoic acid on the surface of the microneedle melts and becomes liquid, prompting the drug in the microneedle to be released.

[0048] The microneedle array matrix is ​​hyaluronic acid and loaded with the antibiotic dexamethasone. After the tridecanoic acid melts, the microneedles melt, and the hyaluronic acid and dexamethasone act together on the affected area to achieve the dual effects of skin moisturizing and treatment.

[0049] The rechargeable power source 1-1, the flexible circuit module 1-2 and the temperature-controlled therapeutic microneedle 1-3 are connected to the flexible substrate through a reflow soldering process, and the control chip and the rechargeable power source are on the upper surface of the flexible substrate; the measurement module and the temperature-controlled therapeutic microneedle are located on the lower surface of the flexible circuit, and the components on the upper surface of the flexible substrate are encapsulated using polydimethylsiloxane (PDMS); the device is ensured to remain insulated from the outside world after encapsulation, and has good biocompatibility, bendability and stretchability.

[0050] like Figure 3As shown, the working flow chart of the patch is displayed. In this embodiment, the mechanical energy of the human body is converted into electrical energy through piezoelectric ceramics to power the charging power supply, and the charging power supply is connected to the patch to power and measure the water content, and then the water content is judged. If it is higher than the threshold, there is no response, and if it is lower than the threshold, the heating release circuit of the microneedle is activated to release the medicine.

[0051] Figure 4 The test results of the skin moisture content of this embodiment are shown. Skin with different moisture contents has different thermal properties and thermal responses.

[0052] Figure 5 The microneedles without tridecanoic acid (left) and the microneedles with tridecanoic acid (right) are shown. It can be seen that the surface morphology of the microneedles with tridecanoic acid has changed compared with the left picture.

[0053] Figure 6 This example was demonstrated in a mouse model of atopic dermatitis, with the microneedle patch fixed on the back of the mouse. The healthy group was healthy mice without disease, the dermatitis group was mice with atopic dermatitis without any treatment, and the treatment group was mice with atopic dermatitis treated with dexamethasone hyaluronic acid microneedles. Inflammatory responses can cause changes in the size of the spleen. It can be seen that after 14 days of treatment with this device, the spleen length of the treatment group was significantly smaller than that of the dermatitis group, with significant statistical differences, indicating that this microneedle patch can effectively act on atopic dermatitis.

[0054] Example 2

[0055] This embodiment provides a method for preparing a self-powered wearable integrated diagnosis and treatment patch for atopic dermatitis, which specifically includes the following steps:

[0056] Step 1: Design of flexible circuit board: Use Jiali Chuang electronic design automation software to design the circuit and pattern the polyimide film to obtain a flexible substrate.

[0057] Step 2, welding of the flexible circuit board; integrating the rechargeable power supply, flexible circuit module and temperature-controlled therapeutic microneedles on a flexible substrate; wherein the control chip in the flexible circuit module is integrated on the upper layer of the flexible substrate, and the measurement module reflow soldering technology is integrated on the bottom layer of the flexible substrate, and the various modules of the circuit are electrically connected, and the final circuit size is a double-layer flexible circuit board with a diameter of 2 cm.

[0058] Step 3: Use PDMS to encapsulate the upper surface of the circuit, that is, the side with the control chip, in small amounts and multiple times to ensure that the device remains insulated from the outside world after encapsulation, and cure it at 80°C for 2 hours. When encapsulating, be careful not to let PDMS make the wires stick together or to encapsulate too much, which will reduce the deformability of the device.

[0059] Furthermore, the preparation steps of a temperature-controlled therapeutic microneedle array of dexamethasone hyaluronic acid microneedle encapsulated with tridecanoic acid are as follows:

[0060] Step 11, preparation of hyaluronic acid microneedles; prepare a hyaluronic acid aqueous solution, dissolve hyaluronic acid in water, and the concentration of hyaluronic acid in the solution is 150 mg / ml.

[0061] Step 12: Add dexamethasone sodium phosphate to the hyaluronic acid solution of step 1, and stir the solution thoroughly for more than 2 hours using a stirring bar and a magnetic stirrer. The concentration of dexamethasone sodium phosphate in the final mixed solution is about 2.5 μg / ml.

[0062] Step 13, placing the solution obtained in step 2 into a microneedle mold, repeatedly evacuating the mold in a vacuum drying oven to remove bubbles, and then drying for 24 hours and then demolding to obtain a microneedle array matrix;

[0063] Step 14: Place the microneedle array matrix obtained in step 3 flat on a container. Put tridecanoic acid into a spray bottle, heat it in a 70 degree Celsius oven to liquid, and evenly spray it on the surface of the microneedle array to form a uniform coating. After standing at room temperature for ten minutes, a microneedle array coated with tridecanoic acid is obtained.

[0064] Example 3

[0065] This embodiment provides a method for constructing a mouse model of atopic dermatitis treated with an ultrasound patch that integrates treatment and monitoring.

[0066] Step 21, modeling of atopic dermatitis mice. Atopic dermatitis was stimulated in mice using 1% dinitrochlorobenzene solution. 1% dinitrochlorobenzene was repeatedly applied to the foot pads, abdomen, ears and back of mice every day for one week. The appearance of atopic dermatitis-like appearances such as erythema, exudation, and epidermal exfoliation on the skin of the tested parts of the mice was considered a successful modeling. After the modeling was successful, the mice were re-stimulated every two days during the treatment period.

[0067] Step 22: Expose the encapsulated microneedle patch to ultraviolet light in a laminar flow cell culture incubator for 30 minutes to sterilize the patch.

[0068] Step 23: Use a microneedle to insert the patch into the back epidermis of the mouse to fix the device. Tegaderm or other adhesive tapes can be used to help further fix the patch.

[0069] Step 24: Turn on the patch circuit twice a day to test the water content. If the drug is released after the test, replace the microneedle and repeat step 3 to fix the device on the back of the mouse. The whole experiment is carried out twice for 14 consecutive days, each test time is three minutes, and if the drug is released, the microneedle is replaced after one hour.

[0070] It is to be understood that the present invention is described by some embodiments, and it is known to those skilled in the art that various changes or equivalent substitutions may be made to these features and embodiments without departing from the spirit and scope of the present invention. In addition, under the teachings of the present invention, these features and embodiments may be modified to adapt to specific circumstances and materials without departing from the spirit and scope of the present invention. Therefore, the present invention is not limited by the specific embodiments disclosed herein, and all embodiments falling within the scope of the claims of this application are within the scope of protection of the present invention.

Claims

1. A self-powered wearable integrated diagnosis and treatment patch for atopic dermatitis, characterized in that: The patch comprises a rechargeable power source (1-1), a flexible circuit module (1-2) and temperature-controlled therapeutic microneedles (1-3); The rechargeable power source comprises two pieces of lead zirconate titanate piezoelectric ceramics stacked up and down and a stainless steel shell, wherein the two pieces of lead zirconate titanate piezoelectric ceramics are wrapped inside the stainless steel shell; The flexible circuit module of the system includes a measurement module and a control chip, and the control chip controls the measurement module; the flexible circuit module is a double-layer circuit board, wherein the control chip is located on the upper circuit board and the measurement module is located on the lower circuit board; Specifically, the measurement module includes a heating circuit (2-1), a measuring circuit (2-2) and a data extraction circuit (2-3); wherein the heating circuit serves as a heating release circuit for the microneedle, and the control chip generates a signal to power the heating circuit for heating; the measuring circuit is a differential circuit, which is connected to a rechargeable power source as an energy source; the quantity extraction circuit uses the digital-to-analog conversion function of the control chip to enable the pin to read the voltage value of the differential circuit through the analog input and record it, and the heating circuit, the measuring circuit and the data extraction circuit remain electrically connected; The temperature-controlled therapeutic microneedle includes a microneedle array matrix and a temperature-sensitive material. The surface of the microneedle array matrix is ​​coated with the temperature-sensitive material. When the measurement circuit detects that the drug needs to be released, the control chip releases a signal to make the heating release circuit of the microneedle heat the temperature-controlled therapeutic microneedle, and the temperature-sensitive material melts and becomes liquid, prompting the drug in the microneedle to be released. The rechargeable power source, flexible circuit module and temperature-controlled therapeutic microneedles are connected to the flexible substrate through a reflow soldering process, and the control chip and the rechargeable power source are on the upper surface of the flexible substrate; the measurement module and the temperature-controlled therapeutic microneedles are located on the lower surface of the flexible circuit, and the components on the upper surface of the flexible substrate are encapsulated using polydimethylsiloxane.

2. A self-powered wearable integrated diagnosis and treatment patch for atopic dermatitis according to claim 1, characterized in that: The heating circuit is composed of two heating wires RH1 and RH2 connected in series, and the analog output of the control chip opening pin is pulse modulated to generate a pulse signal to power the heating wire; The measuring circuit is composed of two resistors R1 and R2 and two negative temperature coefficient thermistors NTC+ and NTC-; NTC+ and R1 are one path, and NTC- and R2 are two paths connected in parallel to form a differential circuit; One end of the differential circuit is connected to a rechargeable power source, and the other end is connected to a quantity extraction circuit. The quantity extraction circuit extracts voltage values ​​of the two paths, and the control chip releases a signal to power the heating circuit.

3. A self-powered wearable integrated diagnosis and treatment patch for atopic dermatitis according to claim 2, characterized in that: The melting point of the temperature sensitive material is 40-42 degrees Celsius.

4. A self-powered wearable integrated diagnosis and treatment patch for atopic dermatitis according to claim 3, characterized in that: The thermosensitive material is tridecanoic acid, the microneedle array matrix is ​​hyaluronic acid, and is loaded with antibiotic dexamethasone.

5. A method for preparing a self-powered wearable integrated diagnosis and treatment patch for atopic dermatitis, characterized in that: The following steps are involved: Step 1, designing a flexible circuit board; using electronic design automation software to design a circuit, and patterning a polyimide film to obtain a flexible substrate; Step 2, welding of the flexible circuit board; integrating the rechargeable power source, the flexible circuit module and the temperature-controlled therapeutic microneedles on the flexible substrate; wherein the control chip in the flexible circuit module is integrated on the upper surface of the flexible substrate, the measurement module reflow soldering technology is integrated on the lower surface of the flexible substrate, and the various modules of the circuit are electrically connected; Step 3: Use polydimethylsiloxane to encapsulate the upper surface of the flexible substrate in small amounts multiple times to ensure that the device remains insulated from the outside world after encapsulation, and cure at 80° C. for 2 hours.

6. The method for preparing a self-powered wearable integrated diagnosis and treatment patch for atopic dermatitis according to claim 5, characterized in that: The steps for preparing the temperature-controlled therapeutic microneedle are as follows: Step 11, preparation of hyaluronic acid microneedles; prepare a hyaluronic acid aqueous solution, dissolve hyaluronic acid in water, and the concentration of hyaluronic acid in the solution is 150 mg / ml. Step 12, adding dexamethasone sodium phosphate to the hyaluronic acid solution of step 1, and stirring the solution for more than 2 hours using a stirring bar and a magnetic stirrer, and finally obtaining a mixed solution containing dexamethasone sodium phosphate at an effective concentration; Step 13, placing the solution obtained in step 12 into a microneedle mold, repeatedly evacuating the mold in a vacuum drying oven to remove bubbles, and then drying for 24 hours and then demolding to obtain a microneedle array matrix; Step 14: Place the microneedle array matrix obtained in step 13 flat on a container, put the temperature-sensitive material into a spray bottle, heat it in a 70-degree Celsius oven to a liquid, and then spray it evenly on the surface of the microneedle array to form a uniform coating. After standing at room temperature for ten minutes, a microneedle array coated with the temperature-sensitive material is obtained.

7. The method for preparing a self-powered wearable integrated diagnosis and treatment patch for atopic dermatitis according to claim 6, characterized in that: The effective concentration is 2.5 micrograms per milliliter.

8. A method for constructing a mouse model of atopic dermatitis treated with an integrated treatment and monitoring ultrasound patch, using the patch as described in any one of claims 1 to 4, characterized in that: The following steps are involved: Step 21, modeling of mice with atopic dermatitis; using 1% dinitrochlorobenzene solution to stimulate atopic dermatitis in mice, and applying 1% dinitrochlorobenzene to the foot pads, abdomen, ears and back of mice every day for one week. The modeling is considered successful when atopic dermatitis-like appearance such as erythema, exudation, and epidermal exfoliation appears on the skin of the tested parts of the mice. After the modeling is successful, the mice are re-stimulated every two days during the treatment period; Step 22, exposing the patch to ultraviolet light for 30 minutes in a laminar flow cell culture incubator to sterilize the patch; Step 23, using the temperature-controlled therapeutic microneedles on the patch to insert the patch into the back epidermis of the mouse to complete the fixation of the device; Step 24, open the patch circuit twice a day to detect the water content. If the drug is released after the test, replace the microneedle and repeat step 23 to fix the device on the back of the mouse. The whole experiment is carried out twice on the specific mice for 14 consecutive days, each test time is three minutes, and if there is drug release, the microneedle is replaced after one hour.

Citation Information

Patent Citations

  • Apparatus for treatment of dermatological conditions

    CN101102815A

  • Intelligent wireless body temperature and excretion event detecting sensor

    CN106137145A

  • Wearable remote control thermal response microneedle array patch and preparation method thereof

    CN111956948A

  • Gene editing microneedle for treating inflammatory skin diseases and application thereof

    CN112807273A

  • Microneedle chip and preparation method thereof

    CN115092875A